FY2025 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Analysts at HC Wainwright lowered their FY2025 earnings per share estimates for PolyPid in a research report issued to clients and investors on Wednesday, November 12th. HC Wainwright analyst B. Folkes now expects that the company will earn ($2.06) per share for the year, down from their prior estimate of ($2.02). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2025 earnings at ($0.38) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($0.70) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at $1.95 EPS.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.17.

Other analysts have also issued reports about the stock. Roth Capital lowered their target price on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings restated a “sell (e+)” rating on shares of PolyPid in a research note on Wednesday, October 8th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $13.00 target price (down from $15.00) on shares of PolyPid in a research report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.40.

PolyPid Stock Up 0.3%

Shares of PolyPid stock opened at $3.64 on Monday. The stock’s fifty day moving average is $3.50 and its two-hundred day moving average is $3.37. PolyPid has a 52 week low of $2.30 and a 52 week high of $3.93. The company has a market capitalization of $57.88 million, a PE ratio of -1.22 and a beta of 1.53.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AIGH Capital Management LLC increased its position in PolyPid by 27.0% during the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after purchasing an additional 253,727 shares during the period. Lumbard & Kellner LLC purchased a new stake in shares of PolyPid in the 2nd quarter worth approximately $135,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after purchasing an additional 3,500 shares in the last quarter. 26.47% of the stock is currently owned by institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.